BeiGene

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

- Primary Endpoint of  Statistical Superiority Related to Deep Response (VGPR  or Better ) Was Not Met;  However, Zanubrutinib Demonstrated More Frequent VGPRs (28.4% vs.19.2% in Overall Population)   - Zanubrutinib Demonstrated Advantages in Safety and Tolerability Compared to Ibrutinib

BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

- Oral presentation on data from Phase 1b trial in patients with platinum-resistant ovarian cancer - Oral presentation on data from Phase 1b trial in patients with platinum-resistant ovarian cancer

BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019

Oral  presen tations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphoma

BeiGene Announces Clinical Data on BRUKINSA™ (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting

Alnylam Pharmaceuticals

Global Blood Therapeutics

Novartis

Vertex Pharmaceuticals

Here's why the FDA recently approved five new drugs way ahead of schedule.

5 New Drug Approvals the FDA Gave Top Priority

It’s a good bet that not many who follow the pharmaceutical industry were familiar with the Chinese company BeiGene (NASDAQ:BGNE).

BeiGene Shares Climb Nearly 50% After Amgen Deal

CAMBRIDGE, Mass. and BEIJING, China, Nov.  23, 2019  (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced preliminary clinical data from a Phase 2 clinical trial of its investigational anti-PD-1 antibody tislelizumab in combination with chemotherapy in patients with gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC) that were presented in a poster at the European Society for Medical Oncology (ESMO) Asia 2019 Congress in Singapore.

BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress

- This marks the first FDA approval for BeiGene

U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

Amgen

Folks who haven’t been paying attention to the absolutely huge potential happening in biotech stocks right now -- both in the U.S. and other parts of the world -- have been put on notice.

This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma

Zai Lab Ltd.

BeiGene and Zai Lab offer two ways to invest in what could be a big opportunity.

Buy These 2 Stocks to Access China's Huge Healthcare Market

Chipotle

Navient

SPS Commerce

The American jobs' market added new positions in October at a better-than-expected pace. Here's how to make the most of it.

4 Stocks to Buy From Sectors With Maximum Job Gains

One of America's largest biotechs will join hands with an industry leader in the rapidly expanding Chinese market.

Here's Why Beigene Stock Is Soaring Today

BeiGene stock rocketed late Thursday after the biotech company announced a collaboration deal that will have Amgen take a $2.7 billion stake in it. That represents 20.5% of BeiGene.

Amgen Is Taking A $2.7 Billion Stake In A Chinese Biotech — Here's Why

• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China 

BeiGene Announces Global Strategic Oncology Collaboration with Amgen

Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors?

BeiGene, Ltd. (BGNE) is a Great Momentum Stock: Should You Buy?

A short-seller report weighed on the Chinese biotech's shares last month.

Why BeiGene Stock Tumbled in September

CAMBRIDGE, Mass. and BEIJING, China, Sept.  30, 2019  (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced clinical data on its investigational anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib that were presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.

BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019

CAMBRIDGE, Mass. and BEIJING, China, Sept.  26, 2019  (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in five poster presentations at the European Society for Medical Oncology (ESMO) Congress 2019, taking place September 27 – October 1, 2019 in Barcelona, Spain.

BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019

BEIJING, China and CAMBRIDGE, Mass., Sept.  22, 2019  (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced clinical results on its investigational anti-PD-1 antibody tislelizumab from three ongoing clinical trials in China. These new or updated data were presented in five of the seven oral presentations on tislelizumab at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), taking place September 18-22, 2019 in Xiamen, China. Additional BeiGene clinical data being presented at CSCO include four poster presentations on tislelizumab, zanubrutinib, and pamiparib.

BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

BEIJING, China and CAMBRIDGE, Mass., Sept.  11, 2019  (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-1 antibody tislelizumab, its investigational BTK inhibitor zanubrutinib, and its investigational PARP inhibitor pamiparib, will be presented in seven oral presentations and four poster presentations at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), taking place September 18-22, 2019 in Xiamen, China.

BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

CAMBRIDGE, Mass. and BEIJING, China, Sept.  03, 2019  (GLOBE NEWSWIRE) --  BeiGene, Ltd.  (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the Morgan Stanley 17th Annual Global Healthcare Conference in New York, NY. The presentation is scheduled for 1:30 p.m. EDT on Tuesday, September 10, 2019.

BeiGene to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.

BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA

CAMBRIDGE, Mass. and BEIJING, China, Aug.  21, 2019  (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for zanubrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The FDA granted Priority Review for the NDA and has set a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2020. This follows the FDA’s Breakthrough Therapy designation for zanubrutinib in this setting earlier this year.

BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Alibaba

Baozun

The trade war has made Chinese stocks dirt cheap. The time to buy them is now and these three could be great long-term positions.

3 Ways to Play the Historic Bargain In Chinese Stocks

China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.

Here's Why BeiGene Lost 11.6% in the First Half of 2019

Shares have risen by 230% since my initial recommendation but are essentially flat since my January 2018 update.

News for BeiGene Stock (BGNE)